Company / Accounts Receivable
NeoGenomics Laboratories, Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$159.2M
FY2025
5-year range
$112.1M / $159.2M
FY2021-FY2025
Trend
+5.8%
vs FY2024
Sector context
#78 of 138
Health Care
What the data says
At $159M, NeoGenomics Laboratories, Inc.'s accounts receivable ranks #78 of 138 in the Health Care sector. Accounts Receivable has increased for 9 consecutive years, from $56M in FY2016 to $159M in FY2025.
Based on SEC 10-K filings.
$159M in FY2025 with a 5-year CAGR of +8.3%.
Improved from $131M to $159M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +10.0%
- 5-Year CAGR
- +8.3%
- 10-Year CAGR
- -
Sector benchmark
#78 of 138 in Health CareTop 57% of 138This company $159.2M Sector average $1.3B
▼
-87.9% below sector average
Key checks
Key Insights
- NeoGenomics Laboratories, Inc.'s accounts receivable has grown for 9 consecutive years.
- 5-year CAGR of +8.3%, indicating consistent growth.
- In FY2025, accounts receivable increased 5.8% year-over-year.
- Ranks #78 out of 138 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $159.2M | +5.8% |
| FY2024 | $150.5M | +14.7% |
| FY2023 | $131.2M | +9.6% |
| FY2022 | $119.7M | +6.8% |
| FY2021 | $112.1M | +4.9% |
| FY2020 | $106.8M | +13.4% |
| FY2019 | $94.2M | +22.5% |
| FY2018 | $76.9M | +27.3% |
| FY2017 | $60.4M | +8.9% |
| FY2016 | $55.5M | +13.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026